Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)
The Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) was set up to provide guidance on the requirements for authorisation of novel veterinary medicines. The advice will be general in nature and will not be related to a particular application or product.
ADVENT is established under the Committee for Medicinal Products for Veterinary Use (CVMP).
ADVENT's tasks include:
- providing advice on the requirements for authorisation of therapies that are new to the veterinary domain (novel therapies);
- supporting dossier evaluation and referrals for novel therapies;
- international cooperation on novel therapy related issues;
- advising, through the CVMP, to the European Commission;
- contributing to novel therapy related workshops and training.
For more information, see veterinary scientific guidelines: novel therapies.
Mandate, rules of procedure and work programme
More information on ADVENT's responsibilities and composition is available in the following documents:
ADVENT is composed of experts selected by the CVMP from the European experts list. The core group members will generally be members of the CVMP or one of its Working Parties, but national experts may also be nominated.
Members of the ADVENT core group should have:
- a broad knowledge of the scientific areas related to marketing authorisation; and
- specific scientific expertise in pharmaceutical and/or immunological quality, safety and/or efficacy.
When generating advice on a particular novel therapy, the ADVENT core group will assemble a specialist expert group (topic group), usually of between four and six additional experts, with specialist knowledge of the therapy concerned.
Below (in alphabetical order of surname) are the current members of the working group. The members' declarations of interests are available in the European expert list.